The collaboration will make use of Fluidigm's automated microfluidic systems to accelerate the design of panels for translational and clinical researchers.
The two companies hope to provide translational researchers a faster, more comprehensive option for the design and validation of Accel-Amplicon panels.
The companies will offer CDI's human induced pluripotent stem cell-derived tissue cells with Nanion's ion channel drug discovery and screening platform.
Separately, FlowJo and Cytapex Bioinformatics said they have partnered to provide bioinformatics consulting and services for flow cytometry data analysis.
Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.
